Abstract
A computer program for retrosynthetic planning helps develop multiple
"synthetic contingency" plans for hydroxychloroquine, a promising but
yet unproven medication against COVID-19. These plans are designed to
navigate, as much as possible, around known and patented routes and to
commence from inexpensive and diverse starting materials, such as to
ensure supply in case of anticipated market shortages of the commonly
used substrates.